STOCK TITAN

Evolus Inc - EOLS STOCK NEWS

Welcome to our dedicated news page for Evolus (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Evolus's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Evolus's position in the market.

Rhea-AI Summary
Evolus, Inc. has launched Nuceiva® (botulinum toxin type A) in Italy, one of the largest aesthetic toxin markets in Europe. The product is now available for direct order and delivery to customers. Evolus aims to expand its presence in the dynamic European market and partner with GP Dermal Solution, a leading company in the Italian cosmetic and wellness sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
-
Rhea-AI Summary
Evolus, Inc. announced that it has completed one million Jeuveau® redemptions through its Evolus Rewards™ patient loyalty program. The program offers enrolled patients $40 off Jeuveau® treatments every 90 days and has seen significant growth since its launch in 2020. Over 600,000 patients have enrolled, with 96% of them returning for subsequent treatments. The majority of enrolled patients are millennials or younger, which is a highly desirable demographic for providers in the aesthetics industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.99%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.99%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
conferences
Evolus Inc

Nasdaq:EOLS

EOLS Rankings

EOLS Stock Data

743.51M
38.80M
13.05%
77.11%
7.56%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
Newport Beach

About EOLS

evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.